Roflumilast: clinical benefit in patients suffering from COPD
نویسندگان
چکیده
منابع مشابه
Roflumilast in COPD.
We read with interest the Point and Counterpoint editorials in CHEST (May 2014) by Suissa and Rabe 1 and Rho et al 2 about the appropriateness of industry-sponsored rofl umilast trials. In the editorials, reference was made to the level of patient withdrawal as well as to the level of side eff ects experienced by patients receiving this drug during clinical trials. 2 In our real-world clinical ...
متن کاملQuantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
BACKGROUND When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes not the most efficient way to reduce uncertainty. Instead, approaches such as value of informatio...
متن کاملDoes roflumilast induce phagocytic activity in COPD patients?
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be f...
متن کاملEfficacy and Safety of Roflumilast in Korean Patients with COPD
PURPOSE Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV₁) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This study evaluated the efficacy and safety of roflumilast in Korean patients with COPD and compared the effica...
متن کاملVulnerable COPD patients with comorbidities: the role of roflumilast
Roflumilast is a selective phosphodiesterase-4 (PDE-4) inhibitor that was approved by the US Food and Drug Administration in February 2011 for the management of chronic obstructive pulmonary disease (COPD). Literature was retrieved through PubMed using the terms "roflumilast" and "COPD". Reference citations from publications identified were also reviewed. All articles published in English using...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Clinical Respiratory Journal
سال: 2010
ISSN: 1752-6981
DOI: 10.1111/j.1752-699x.2010.00224.x